Leerink Partners stays Outperform on Neurogene (NGNE) following Q4 results; cites de-risked path
Tweet Send to a Friend
Leerink Partners analyst Mani Foroohar reiterated an Outperform rating and $70.00 price target on Neurogene (NASDAQ: NGNE)The analyst commented, "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
